Skip to main content

Envisioning how to advance the MASH field.

Publication ,  Journal Article
Allen, AM; Younossi, ZM; Diehl, AM; Charlton, MR; Lazarus, JV
Published in: Nat Rev Gastroenterol Hepatol
October 2024

Since 1980, the cumulative effort of scientists and health-care stakeholders has advanced the prerequisites to address metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent chronic non-communicable liver disease. This effort has led to, among others, the approval of the first drug specific for metabolic dysfunction-associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis). Despite substantial progress, MASLD is still a leading cause of advanced chronic liver disease, including primary liver cancer. This Perspective contextualizes the nomenclature change from nonalcoholic fatty liver disease to MASLD and proposes important considerations to accelerate further progress in the field, optimize patient-centric multidisciplinary care pathways, advance pharmacological, behavioural and diagnostic research, and address health disparities. Key regulatory and other steps necessary to optimize the approval and access to upcoming additional pharmacological therapeutic agents for MASH are also outlined. We conclude by calling for increased education and awareness, enhanced health system preparedness, and concerted action by policy-makers to further the public health and policy agenda to achieve at least parity with other non-communicable diseases and to aid in growing the community of practice to reduce the human and economic burden and end the public health threat of MASLD and MASH by 2030.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Rev Gastroenterol Hepatol

DOI

EISSN

1759-5053

Publication Date

October 2024

Volume

21

Issue

10

Start / End Page

726 / 738

Location

England

Related Subject Headings

  • Non-alcoholic Fatty Liver Disease
  • Humans
  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Allen, A. M., Younossi, Z. M., Diehl, A. M., Charlton, M. R., & Lazarus, J. V. (2024). Envisioning how to advance the MASH field. Nat Rev Gastroenterol Hepatol, 21(10), 726–738. https://doi.org/10.1038/s41575-024-00938-9
Allen, Alina M., Zobair M. Younossi, Anna Mae Diehl, Michael R. Charlton, and Jeffrey V. Lazarus. “Envisioning how to advance the MASH field.Nat Rev Gastroenterol Hepatol 21, no. 10 (October 2024): 726–38. https://doi.org/10.1038/s41575-024-00938-9.
Allen AM, Younossi ZM, Diehl AM, Charlton MR, Lazarus JV. Envisioning how to advance the MASH field. Nat Rev Gastroenterol Hepatol. 2024 Oct;21(10):726–38.
Allen, Alina M., et al. “Envisioning how to advance the MASH field.Nat Rev Gastroenterol Hepatol, vol. 21, no. 10, Oct. 2024, pp. 726–38. Pubmed, doi:10.1038/s41575-024-00938-9.
Allen AM, Younossi ZM, Diehl AM, Charlton MR, Lazarus JV. Envisioning how to advance the MASH field. Nat Rev Gastroenterol Hepatol. 2024 Oct;21(10):726–738.

Published In

Nat Rev Gastroenterol Hepatol

DOI

EISSN

1759-5053

Publication Date

October 2024

Volume

21

Issue

10

Start / End Page

726 / 738

Location

England

Related Subject Headings

  • Non-alcoholic Fatty Liver Disease
  • Humans
  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics